about
The distinctive nature of adenocarcinoma of the lungSwitch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study.Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer.Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥ 75 years with impaired performance status.Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis.Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinomaBevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxelRole of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials.No Advantage in Survival With Targeted Therapies as Maintenance in Patients With Limited and Extensive-Stage Small Cell Lung Cancer: A Literature-Based Meta-Analysis of Randomized Trials.Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trialsRisk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis.Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials.Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis.A husband and a wife with simultaneous presentation of glioblastoma multiforme: a case report.No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide.PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials.The third line of treatment for metastatic prostate cancer patients: Option or strategy?Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.Low dose versus standard dose of corticosteroids in the management of adverse events of special interest from abiraterone acetate: data from a literature-based meta-analysis.Advances in systemic therapy for metastatic breast cancer: future perspectives.Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility.Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials.New molecular therapies in patients with advanced Hepatocellular Cancer in second line of treatment: Is a real defeat?: Results from a literature based meta-analysis of randomized trials.Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial.A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers.Neoadjuvant chemotherapy and radical radiotherapy associated with cetuximab for laryngeal cancer in a pancreas and renal recipient.Is still there a role for IL-2 for solid tumors other than melanoma or renal cancer?The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials.An exceptional overall survival using bevacizumab beyond progression in a patient with non-small cell lung cancer.Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience.Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer.PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin ChemotherapyIsolated Testicular Metastasis from Prostate Cancer.Carboplatin, methotrexate, vinblastine, and epirubicin (M-VECa) as salvage treatment in patients with advanced bladder cancer: a phase II study.Effects of abiraterone acetate on chronic kidney disease in 2 patients with metastatic castration-resistant prostate cancer.Is there still a place for docetaxel rechallenge in prostate cancer?Bevacizumab in small cell lung cancer.Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis.Time for a revision on the role of PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatment for patients with metastatic hormone-refractory prostate cancer.
P50
Q26781159-F2D8EEF1-42FA-494E-B5B3-CCA764995E9DQ33421361-997C8DC4-6D84-4CB6-B0F8-F3E9E6E2A85DQ33421476-36BEACF0-DF8F-441E-84A0-ECC76BBE9484Q33424849-9E1351CF-5ADD-4C1C-BFAC-DDED1C86AEB4Q33431544-450F318E-CA34-49CE-80AF-D15B1D3D80C2Q33631760-D5FEBB60-8316-41B8-8A48-B7F41D71F935Q35433194-3AC42EB5-B657-4C68-9082-C56656C67052Q36012922-30301314-AF59-4BC0-BBA3-B6667C9AB586Q36062002-17DBC3E5-598F-49DF-B52E-6E608104B348Q36175852-58582535-FC31-42DE-871B-E01E6F04DFE8Q36305417-62B5C46D-4B48-4EEB-818B-B1B7337FBA49Q36352650-E29A3CB5-478A-4484-8150-B538D7B19FF3Q37282982-2235A2F2-FA6C-40B7-B52A-1E3A4165EADCQ37350800-17138693-CECA-4A6C-BC88-09DA36B1B558Q38241095-4728EC48-BE44-4E67-A524-DC5629125C09Q38246587-89F95643-3756-4EC9-BE84-D13DA0E57413Q38519778-FA978A40-011C-48A7-9B00-89EF26B4B4CCQ38530028-A3EE783B-5C0D-4714-A635-7EE7694021B3Q38602626-9FE18E2F-B9BE-4A11-B9FA-64E1B611F610Q38681576-39ACC705-0B9D-45AF-BA12-B641F47FB0A5Q38734804-AC2219CB-C818-406F-9F72-9211BD2915D6Q38772576-B3622247-740C-4DD4-9155-CC28A9D14E63Q38785592-80AEE819-C546-453F-AED4-D3F0CC42E294Q38845975-2033B2D2-E6FA-4E24-89A1-A1007E53E009Q38850688-5E3EE2FF-05AB-4EB2-A08C-F618F4DEB3DCQ38899807-1D3E37D4-6740-4DB7-920F-542F01506F24Q38904256-5F019CFF-6728-4910-95B3-2CB740C5ACF2Q39045561-F835F9F0-ACF2-4648-8B50-A383D3BEF199Q39153341-D225BB86-7EC5-4EF5-A789-D1392FEF3657Q40487286-91D1FD2C-BF4B-41F7-9144-04AB1C8C6D4BQ40859512-ADADB578-4E1A-4418-B6BD-5AC417F52DE7Q41283989-5AE8247C-F28F-42C0-99B2-E19EDB2D545CQ41348551-A5208B73-C0E6-4C48-92F0-51C37EBD2445Q41493734-1823DF40-9DF7-4A0B-9805-C254D8CC9A8AQ41686856-1A99000D-8BE4-405F-B224-A3EC936AA6B6Q42015004-921297F4-7F1A-4CD9-A410-CE8F9358C0EAQ42096514-296ED4CE-4489-4F91-8710-F921DB9016FDQ42359058-0F37D7D6-A96F-4B5C-8EDA-8AE47F8CCD8FQ45207496-2F712788-1EDF-4182-82E8-A790BF7A10E4Q45389025-25A1D73C-780B-401D-B31F-A9310ED1B7D4
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giandomenico Roviello
@ast
Giandomenico Roviello
@en
Giandomenico Roviello
@es
Giandomenico Roviello
@nl
Giandomenico Roviello
@sl
type
label
Giandomenico Roviello
@ast
Giandomenico Roviello
@en
Giandomenico Roviello
@es
Giandomenico Roviello
@nl
Giandomenico Roviello
@sl
prefLabel
Giandomenico Roviello
@ast
Giandomenico Roviello
@en
Giandomenico Roviello
@es
Giandomenico Roviello
@nl
Giandomenico Roviello
@sl
P106
P1153
54895217200
P21
P31
P496
0000-0001-5504-8237